Table 3.
Treatment and Outcome of Patients with COVID-19.
| All (n=22) | Liver injury | p value | ||||||
|---|---|---|---|---|---|---|---|---|
| Present (n=15) | Absent (n=7) | |||||||
| Treatment before diagnosis of COVID-19 | ||||||||
| Antibiotics | 7 (32) | 6 (40) | 1 (14) | 0.35 | ||||
| Antipyretics | 7 (32) | 7 (47) | 0 | 0.051 | ||||
| Treatment of COVID-19 | ||||||||
| Ciclesonide | 7 (32) | 6 (40) | 1 (14) | 0.35 | ||||
| Favipiravir | 9 (41) | 7 (47) | 2 (29) | 0.65 | ||||
| Ventilator | 4 (18) | 3 (20) | 1 (14) | 1.00 | ||||
| Outcome | ||||||||
| Death | 2 (9) | 1 (7) | 1 (14) | 1.00 | ||||
| Hospitalization (days) | 16 (12–21) | 19 (15–26) | 14 (9–15) | 0.13 | ||||
Continuous variables are shown as median (IQR), and categorical variables are shown as number (%). The p values for comparing the patients with and without liver injury were calculated using the Mann-Whitney U test and Fisher’s exact test.